(UroToday.com) Dr. Noel Clarke first discussed presentation 617, the MANSMED trial. He reviewed the trial schemia, which randomized 124 high-risk prostate cancer patients 1:1 to either standard of care or standard of care plus metformin.
(UroToday.com) Dr. Noel Clarke first discussed presentation 617, the MANSMED trial. He reviewed the trial schemia, which randomized 124 high-risk prostate cancer patients 1:1 to either standard of care or standard of care plus metformin.